Literature DB >> 32478860

Hemolytic markers following the transfusion of uncrossmatched, cold-stored, low-titer, group O+ whole blood in civilian trauma patients.

Ian M Harrold1,2, Jansen N Seheult1,2, Louis H Alarcon3,4, Alain Corcos3,4, Jason L Sperry3,4, Darrell J Triulzi1,2, Mark H Yazer1,2.   

Abstract

BACKGROUND: Low-titer group O whole blood (LTOWB) is increasingly being used in the civilian trauma setting, although there is a risk of hemolysis. This study evaluated the impact on hemolytic markers following the transfusion of 4 or more units of uncrossmatched LTOWB.
METHODS: Civilian adult trauma patients who received four or more units of leukoreduced group O+, low-titer (<50 anti-A and anti-B), platelet-replete uncrossmatched whole blood during their initial resuscitation and who survived for more than 24 hours after the transfusion were included in this retrospective study. Lactate dehydrogenase (LDH), total bilirubin, haptoglobin, potassium, and creatinine were evaluated on the day of LTOWB transfusion (Day 0) and the next 3 days. Blood product administration over the first 24 hours of admission was recorded.
RESULTS: There were 54 non-group O and 23 group O recipients of four or more LTOWB units. The median (interquartile range [IQR]) number of transfused LTOWB units was 4 (4-5) and 4 (4-4), respectively, the maximum number in both groups was eight. The non-group O patients received a median (IQR) volume of 1470 mL (1368-2052) of ABO-incompatible plasma. Comparing the non-group O to the group O recipients, there were no significant differences in the haptoglobin, LDH, total bilirubin, potassium, or creatinine concentrations at any of the time points. There were no reported transfusion reactions.
CONCLUSION: Receiving at least four LTOWB units was not associated with biochemical or clinical evidence of hemolysis.
© 2019 AABB.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32478860     DOI: 10.1111/trf.15629

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  5 in total

Review 1.  Low-Titer Group O Whole-Blood Resuscitation in the Prehospital Setting in Israel: Review of the First 2.5 Years' Experience.

Authors:  Dan Levin; Maoz Zur; Eilat Shinar; Tzadok Moshe; Avishai M Tsur; Roy Nadler; Mark H Yazer; Danny Epstein; Guy Avital; Shaul Gelikas; Elon Glassberg; Avi Benov; Jacob Chen
Journal:  Transfus Med Hemother       Date:  2021-10-06       Impact factor: 3.747

2.  Recent Developments in Emergency Blood Transfusion.

Authors:  Hans-Gert Heuft; Mark H Yazer
Journal:  Transfus Med Hemother       Date:  2021-10-28       Impact factor: 3.747

3.  The Evolution of Blood Product Use in Trauma Resuscitation: Change Has Come.

Authors:  Mark H Yazer
Journal:  Transfus Med Hemother       Date:  2021-11-02       Impact factor: 3.747

4.  Prehospital low titer group O whole blood is feasible and safe: Results of a prospective randomized pilot trial.

Authors:  Frank X Guyette; Mazen Zenati; Darrell J Triulzi; Mark H Yazer; Hunter Skroczky; Barbara J Early; Peter W Adams; Joshua B Brown; Louis Alarcon; Matthew D Neal; Raquel M Forsythe; Brian S Zuckerbraun; Andrew B Peitzman; Timothy R Billiar; Jason L Sperry
Journal:  J Trauma Acute Care Surg       Date:  2022-01-25       Impact factor: 3.697

Review 5.  There and back again: the once and current developments in donor-derived platelet products for hemostatic therapy.

Authors:  Valery J Kogler; Moritz Stolla
Journal:  Blood       Date:  2022-06-30       Impact factor: 25.476

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.